These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15051626)

  • 21. Effect of a kappa-opioid agonist, i.v. JNJ-38488502, on sensation of colonic distensions in healthy male volunteers.
    Floyd BN; Camilleri M; Busciglio I; Sweetser S; Burton D; Wong GY; Kell S; Khanna S; Hwang S; Zinsmeister AR
    Neurogastroenterol Motil; 2009 Mar; 21(3):281-90. PubMed ID: 18823290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kappa opioid agonists suppress chloroquine-induced scratching in mice.
    Inan S; Cowan A
    Eur J Pharmacol; 2004 Oct; 502(3):233-7. PubMed ID: 15476749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of visceral pain and inflammation by protease-activated receptors.
    Vergnolle N
    Br J Pharmacol; 2004 Apr; 141(8):1264-74. PubMed ID: 15051630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
    Lester PA; Traynor JR
    Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The individual and combined effects of U50,488, and flurbiprofen axetil on visceral pain in conscious rats.
    Kitamura T; Ogawa M; Yamada Y
    Anesth Analg; 2009 Jun; 108(6):1964-6. PubMed ID: 19448232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kappa opioids as potential treatments for stimulant dependence.
    Prisinzano TE; Tidgewell K; Harding WW
    AAPS J; 2005 Oct; 7(3):E592-9. PubMed ID: 16353938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Irritable bowel syndrome: pathophysiology and (future) treatment options].
    de Schryver AM; Samsom M
    Ned Tijdschr Geneeskd; 2002 Jan; 146(1):12-7. PubMed ID: 11802330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripherally-acting opioids.
    Smith HS
    Pain Physician; 2008 Mar; 11(2 Suppl):S121-32. PubMed ID: 18443636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-addictive orally-active kappa opioid agonists for the treatment of peripheral pain in rats.
    Beck TC; Reichel CM; Helke KL; Bhadsavle SS; Dix TA
    Eur J Pharmacol; 2019 Aug; 856():172396. PubMed ID: 31103632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gonadal hormones decrease temporomandibular joint kappa-mediated antinociception through a down-regulation in the expression of kappa opioid receptors in the trigeminal ganglia.
    Clemente-Napimoga JT; Pellegrini-da-Silva A; Ferreira VH; Napimoga MH; Parada CA; Tambeli CH
    Eur J Pharmacol; 2009 Sep; 617(1-3):41-7. PubMed ID: 19567249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DAMGO and 6beta-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens.
    Al-Khrasani M; Spetea M; Friedmann T; Riba P; Király K; Schmidhammer H; Furst S
    Brain Res Bull; 2007 Oct; 74(5):369-75. PubMed ID: 17845912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ZYKR1, a novel, potent, and peripherally selective kappa opioid receptor agonist reduces visceral pain and pruritus in animal models.
    Jain MR; Patel RB; Prajapati KD; Vyas P; Bandyopadhyay D; Prajapati V; Bahekar R; Patel PN; Kawade HM; Kokare DM; Pawar V; Desai R
    Eur J Pharmacol; 2022 Jun; 924():174961. PubMed ID: 35443192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of peripherally restricted κ opioid receptor agonists on pain-related stimulation and depression of behavior in rats.
    Negus SS; O'Connell R; Morrissey E; Cheng K; Rice KC
    J Pharmacol Exp Ther; 2012 Mar; 340(3):501-9. PubMed ID: 22128346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agonist-induced regulation and trafficking of kappa opioid receptors.
    Liu-Chen LY
    Life Sci; 2004 Jun; 75(5):511-36. PubMed ID: 15158363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Visceral sensitivity perturbation integration in the brain-gut axis in functional digestive disorders.
    Bonaz B
    J Physiol Pharmacol; 2003 Dec; 54 Suppl 4():27-42. PubMed ID: 15075447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists.
    Mangel AW; Fehnel SE
    Neurogastroenterol Motil; 2008 Oct; 20(10):1086-93. PubMed ID: 18826559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The brain-gut axis in irritable bowel syndrome--clinical aspects.
    Mach T
    Med Sci Monit; 2004 Jun; 10(6):RA125-31. PubMed ID: 15173682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
    Wang JY; Zhao M; Yuan YK; Fan GX; Jia H; Tang JS
    Neuroscience; 2006; 138(4):1319-27. PubMed ID: 16472929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attacking pain at its source: new perspectives on opioids.
    Stein C; Schäfer M; Machelska H
    Nat Med; 2003 Aug; 9(8):1003-8. PubMed ID: 12894165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. kappa-Opioid activity of the four stereoisomers of the peripherally selective kappa-agonists, EMD 60,400 and EMD 61,753.
    Gottschlich R; Krug M; Barber A; Devant RM
    Chirality; 1994; 6(8):685-9. PubMed ID: 7857777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.